Camber Capital Management’s Zymeworks ZYME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-2,865,000
Closed -$17.6M 49
2022
Q3
$17.6M Buy
2,865,000
+865,000
+43% +$5.21M 0.54% 39
2022
Q2
$10.6M Hold
2,000,000
0.46% 36
2022
Q1
$13.1M Buy
2,000,000
+1,200,000
+150% +$10.7M 0.47% 31
2021
Q4
$13.1M Buy
800,000
+50,000
+7% +$1.04M 0.45% 31
2021
Q3
$21.8M Buy
+750,000
New +$24.9M 0.67% 34
2019
Q4
Sell
-1,500,000
Closed -$37.2M 37
2019
Q3
$37.2M Sell
1,500,000
-1,100,000
-42% -$27.6M 1.96% 22
2019
Q2
$57.2M Buy
2,600,000
+434,000
+20% +$7.97M 2.67% 16
2019
Q1
$35M Hold
2,166,000
1.75% 23
2018
Q4
$31.8M Buy
2,166,000
+793,000
+58% +$10.4M 1.51% 26
2018
Q3
$21.6M Buy
1,373,000
+123,000
+10% +$1.76M 0.92% 22
2018
Q2
$18.5M Buy
+1,250,000
New +$19.4M 0.71% 32

Other funds holding ZYME

Camber Capital Management's ZYME Position: Q4 2022 in Review

Camber Capital Management sold out of Zymeworks (ZYME) in Q4 2022, closing a stake of 2,865,000 shares — an estimated $17.6M sold.

Camber Capital Management first reported a position in ZYME in Q2 2018 and held it in 11 quarters. The position peaked at $57.2M in Q2 2019. 96 funds tracked by Wall St. Rank hold ZYME as of Q4 2022.

  • Camber Capital Management reported no remaining Zymeworks position as of Q4 2022 after selling out during the quarter.
  • Camber Capital Management sold 2,865,000 Zymeworks shares in Q4 2022, an estimated $17.6M.
  • Camber Capital Management first reported a position in Zymeworks in Q2 2018 and held it in 11 quarters.
  • Camber Capital Management's Zymeworks position peaked at $57.2M in Q2 2019.
  • 96 funds tracked by Wall St. Rank held Zymeworks as of Q4 2022.

Based on Camber Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.